Anika Therapeutics Announces Date for 2003 Fourth Quarter and Year-End Financial Results Conference Call.

Business Editors

WOBURN, Mass.--(BUSINESS WIRE)--Feb. 18, 2004

Anika Therapeutics, Inc. (NASDAQ: ANIK) today said it plans to issue its fourth quarter and year-end financial results before the opening of the market on February 27, 2004. The company plans to hold a conference call the same day at 11:00 a.m. EST to discuss quarterly financial results, business highlights and outlook. In addition, the company may answer one or more questions concerning business and financial developments and trends, and other business and financial matters affecting the company, some of the responses to which may contain information that has not been previously disclosed.

To listen to the conference call, dial 706-634-1550 approximately 10 minutes before the starting time and reference Anika Therapeutics. In addition, the conference call will be available to interested parties through a live audio Internet broadcast at http://www.anikatherapeutics.com/newset.htm. The call will be archived and accessible on the same web site beginning at 2:00 p.m. EST Friday, February 27, 2004 through 2:00 p.m. EST, Friday, February 25, 2005.

About Anika Therapeutics, Inc.

Headquartered in Woburn, Mass., Anika Therapeutics, Inc. (www.anikatherapeutics.com) develops, manufactures and commercializes therapeutic products and devices intended to promote the repair, protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. In addition to ORTHOVISC(R), a treatment for osteoarthritis of the knee (not approved for sale in the U.S.), Anika markets HYVISC(R) in the U.S. for the treatment of equine osteoarthritis through Boehringer Ingelheim Vetmedica, Inc. and manufactures AMVISC(R) and AMVISC(R) Plus, HA viscoelastic products for ophthalmic surgery, for Bausch & Lomb. It also produces CoEase(TM), which is marketed by Advanced Medical Optics, Inc., STAARVISC(TM)-II distributed by STAAR Surgical Company and Shellgel(TM) for Cytosol Ophthalmics, Inc.